Cantheon Capital

Oxford Cannabinoid Technologies Ltd., established in 2017 and based in Oxford, UK, is a biopharmaceutical company dedicated to researching, developing, and licensing cannabinoid-based compounds and therapies. Its primary focus lies in creating novel treatments for diseases with high unmet medical need, combining cannabinoid medicine with world-class scientific research and drug development. The company's therapeutic areas of interest include inflammatory diseases, oncology, neurological disorders, and pain management.

Psycheceutical is a developer of patented delivery technologies focused on the safe and effective administration of psychedelic pharmaceutical medicines. The company utilizes innovative Janus particles and advanced delivery systems to enhance the bioavailability and dosing control of psychedelic compounds. By targeting specific cells, these technologies aim to improve patient outcomes in various medical applications, particularly for conditions associated with liver diseases and related toxicity. Psycheceutical's mission is to transform conventional treatment paradigms within the medical and pharmaceutical industries through its pioneering approaches to psychedelic therapeutics.

Albert Labs is a biopharmaceutical company dedicated to developing innovative prescription medicines aimed at addressing unmet mental health needs. The organization employs advanced culture technology and natural extraction methods alongside a comprehensive regulatory strategy to enhance the development of mental health drugs. Albert Labs prioritizes solutions that follow an approved, fast-track clinical pathway, specifically utilizing Real World Evidence (RWE) studies, which have been effectively applied in areas such as oncology and the recent development of COVID-19 vaccines. The company is initially focused on commercializing its mycelium-based treatment, KRN-101, to meet urgent patient needs in the mental health sector.

Psyence Group is a life science biotechnology company dedicated to the research, cultivation, and production of psychedelics and natural compounds, particularly psilocybin, to address psychological trauma and related disorders such as anxiety, depression, PTSD, and stress. The company emphasizes the use of these substances within the framework of palliative care and mental wellness. Psyence engages in scientific research and the development of psilocybin medical products for various applications, including clinical use and regulatory-compliant psilocybin-containing products. Additionally, the company is exploring functional mushroom nutraceuticals aimed at treating depression, anxiety, and sleep disorders, contributing to a broader understanding of the therapeutic potential of natural substances in mental health care.

Zelira Therapeutics Limited is a bio-pharmaceutical company based in Perth, Australia, specializing in the development of cannabinoid-based formulations aimed at treating various medical conditions. The company conducts human clinical trials targeting insomnia, autism, and opioid reduction, while also engaging in pre-clinical research to explore the effects of cannabinoids on breast, brain, and pancreatic cancers. Additionally, Zelira is investigating the potential of cannabinoid formulations to address diabetes-associated cognitive decline. The company collaborates with CannPal Pty Ltd and St Vincent's Hospital on opioid reduction studies. Formerly known as Zelda Therapeutics Limited, it rebranded to Zelira Therapeutics Limited in December 2019.